# 18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

> **NCT03930173** · EARLY_PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Secondary Malignant Neoplasm of Brain and Cerebral Meninges

## Interventions

- **DRUG:** 18F-fluciclovine
- **DEVICE:** PET/CT of the brain

## Key facts

- **NCT ID:** NCT03930173
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-02
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930173, "18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03930173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*